MedTrace Logo

Immune Response Following COVID-19 Vaccination

NCT04736524 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2021-02-03

No results posted yet for this study

Summary

Few trials have reported the safety and efficacy of the COVID-19 vaccines. However, these trials were mostly focused on post-vaccination adverse events and short-term antibody detection with none monitoring the presence of immunoglobulin G (IgG) in blood at long-term follow-up after the vaccination. This study aims to evaluate the immune response in post-vaccinated individuals across a follow-up period of one year.

Conditions

  • IgM and IgG in Blood

Interventions

OTHER

Rapid antibody test

Serial serology tests on day 21, 90, 180 and 365 following the first dose of the COVID-19 vaccine to detect the temporal trend of the IgM and IgG production in response to the vaccination.

Sponsors & Collaborators

  • Texas Cardiac Arrhythmia Research Foundation

    lead OTHER

Principal Investigators

  • Andrea Natale · Texas Cardiac Arrhythmia Research Foundation

  • Sanghamitra Mohanty · Texas Cardiac Arrhythmia Research Foundation

Eligibility

Min Age
16 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-15
Primary Completion
2022-03-31
Completion
2022-03-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04736524 on ClinicalTrials.gov